This annual one-day symposium, chaired by institute member of the Ó³»´«Ã½ and faculty at Brigham and Women’s Hospital and Harvard Medical School, Dr. Anna Greka, will bring together leading stakeholders to discuss how we can advance the quest for novel therapeutics for kidney diseases, an area of tremendous unmet need. The Kidney-NExT Symposium is a unique forum for shared dialogue between academia and industry leaders, the FDA and patients from across the country to shape the future of kidney treatments.
Thursday, September 30, 2021
Virtual Symposium
Symposium Program
9:00 - 9:05 am
Welcome
Anna Greka
Session 1
Keynote Lecture
Chair: Joe Bonventre
9:05 - 9:25 am
From scientific breakthrough to the clinic: the RNAi revolution
John Maraganore
9:25 - 9:35 am
Q&A
Session 2
Genomics
Chair: Michelle McNulty
9:35 - 9:50 am
The genetic architecture of kidney diseases
Krzysztof Kiryluk
9:50 - 10:00 am
Q&A
10:00 - 10:15 am
Genomics of CKD
Anna Köttgen
10:15 - 10:25 am
Q&A
10:25 - 10:40 am
Insights from single cell genomics
Ayshwarya Subramanian
10:40 - 10:50 am
Q&A
10:50 - 11:00 am
Break
Session 3
Disease mechanisms
Chair: Caroline Fox
11:00 - 11:15 am
Novel mechanisms of CKD and lessons from COVID19 in Germany
Tobias Huber
11:15 - 11:25 am
Q&A
11:25 - 11:40 am
Novel kidney anabolic functions revealed by unbiased profiling
Eugene Rhee
11:40 - 11:50 am
Q&A
11:50 am - 12:05 pm
Anti-nephrin podocytopathy: are we ready for a new paradigm?
Astrid Weins
12:05 - 12:15 pm
Q&A
12:15 - 12:25 pm
Break
(at this time you are invited to grab your lunch to eat during the Fireside Chat)
Session 4
Chairs: Edward Drake II and Kevin Fowler
Fireside Chat
New and exciting therapies on the horizon: the patient voice
12:25 - 12:55 pm
Edward Drake II and Kevin Fowler in discussion with:
Martin Pollak | physician-scientist leader
Aliza Thompson | FDA leader
Caroline Fox | industry leader
12:55 - 1:05 pm
Break
Session 5
New frontiers: from the lab to the clinic
Chair: Astrid Weins
1:05 - 1:20 pm
Novel mechanisms of acute kidney injury
Samir Parikh
1:20 - 1:30 pm
Q&A
1:30 - 1:45 pm
New insights into APOL1 kidney disease
Opeyemi Olabisi
1:45 - 1:55 pm
Q&A
1:55 - 2:10 pm
Progress in clinical trials in Membranous Nephropathy
Fernando Fervenza